Literature DB >> 17172059

Seroprevalence of mumps, varicella and rubella antibodies in children 1-16 years of age in eastern Turkey.

Metin Kaya Gürgöze1, Erdal Yilmaz, Ahmet Gödekmerdan, Zehra Akça, Yaşar Doğan, Saadet Akarsu, A Denizmen Aygün.   

Abstract

In this study, seroprevalence of mumps, varicella and rubella was investigated in 803 unvaccinated children in eastern Turkey whose ages ranged between 1 and 16 years. Mumps IgG, varicella IgG and rubella IgG antibody levels in all children were studied by enzyme-linked immunosorbent assay (ELISA) method. Information regarding socioeconomic characteristics, number of siblings and disease history was gathered for each participant. No significant difference in seropositivity was detected between girls and boys. Seroprevalence of mumps increased with age, with a seropositivity rate of 29.9% in children aged 1-4 years and of 88.8% in those aged 13-16 years. Seroprevalence of varicella increased with age, with a seropositivity rate of 26.8% in children aged 1-4 years and of 90.3% in those aged 13-16 years. Seroprevalence of rubella also increased with age, with a seropositivity rate of 47.3% in the children aged 1-4 years and of 89.2% in those aged 13-16 years. There was a statistically significant increase in the rate of seropositivity with advancing age through the group of 13-16 years old (p < 0.05). In conclusion, in order to avoid mumps, varicella and rubella diseases and their possible complications, children should be vaccinated against these three diseases before the age of two, since seroprevalence increases with age.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172059

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  8 in total

1.  Seroprevalence of IgG Antibodies against Mumps in Bulgarian Children under 18 Years of Age.

Authors:  Milena Karcheva; Galya Gancheva
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

2.  Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain).

Authors:  Lluís Salleras; Angela Domínguez; Pere Plans; Josep Costa; Neus Cardeñosa; Núria Torner; Antoni Plasència
Journal:  Med Microbiol Immunol       Date:  2007-11-15       Impact factor: 4.148

3.  Sero-survey of rubella IgM antibodies among children in Jos, Nigeria.

Authors:  Surajudeen A Junaid; King J Akpan; Atanda O Olabode
Journal:  Virol J       Date:  2011-05-19       Impact factor: 4.099

4.  Rubella Seromarkers and Determinants of Infection among Tanzanian Children and Adolescents in Prevaccination Era: Are We in the Right Track?

Authors:  Mariam M Mirambo; Said Aboud; Uwe Groß; Mtebe Majigo; Martha F Mushi; Stephen E Mshana
Journal:  Int J Prev Med       Date:  2017-01-23

Review 5.  Varicella infection in the Middle East: Prevalence, complications, and vaccination.

Authors:  Mariam Al-Turab; Wassim Chehadeh
Journal:  J Res Med Sci       Date:  2018-04-26       Impact factor: 1.852

6.  Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

Authors:  Lara J Wolfson; Vincent J Daniels; Matthew Pillsbury; Zafer Kurugöl; Cuneyt Yardimci; Jeffrey Kyle; Ener Cagri Dinleyici
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

7.  Serological evidence of acute rubella infection among under-fives in Mwanza: a threat to increasing rates of congenital rubella syndrome in Tanzania.

Authors:  Mariam M Mirambo; Said Aboud; Martha F Mushi; Mwanaisha Seugendo; Mtebe Majigo; Uwe Groß; Stephen E Mshana
Journal:  Ital J Pediatr       Date:  2016-05-25       Impact factor: 2.638

8.  The clinical and economic burden of varicella in the Middle East: a systematic literature review.

Authors:  Nawal Al Kaabi; Fatma Mohd Ali Sultan Al Olama; Mamoun Al Qaseer; Idris Al Ubaidani; Ener Cagri Dinleyici; Wail Ahmad Hayajneh; Abdul Rahman Bizri; Maysoon Loulou; Tidiane Ndao; Lara J Wolfson
Journal:  Hum Vaccin Immunother       Date:  2019-09-03       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.